Future studies will also use CT26 mouse colon cancer cells and both orthotopic and genetic models of colon cancer to investigate the relative antitumorigenic effects of NR4A1 antagonists on tumors and immune cells and further develop optimal drug candidates for pre-IND and phase 1 clinical trials. This evidence concerns the gene NR4A1 and malignant colon neoplasm.